#drug development

3개의 글

July 28, 2026

Voronoi (KOSDAQ 310210) Stock Outlook 2026: Brain-Penetrant Precision Oncology vs. the Clinical Binary

Voronoi (KOSDAQ 310210) 2026 stock outlook. A deep look at its brain-penetrant precision kinase oncology platform, the out-licensing royalty and milestone business model, the clinical-binary, cash-burn and dilution risks, Korean biotech peer comparison, and what foreign investors should know about KRW currency exposure.

Voronoi 310210 KOSDAQ

July 10, 2026

ABL Bio (KOSDAQ 298380) Stock Outlook 2026: The Grabody-B Platform and the Reality of Big-Pharma Licensing

ABL Bio (KOSDAQ 298380) 2026 stock analysis: the Grabody-B blood-brain-barrier shuttle platform, the Sanofi Parkinson's licensing deal, 4-1BB bispecific immuno-oncology, ADC pipeline, milestone-and-royalty revenue, and the clinical and cash-burn risks.

ABL Bio 298380 bispecific antibody

July 8, 2026

Ildong Pharmaceutical Stock Outlook 2026 (KRX: 249420): OTC Cash Cow vs. Drug R&D Burn

Ildong Pharmaceutical (KRX: 249420) 2026 stock analysis: Aronamin and GQ-Lab OTC brand cash cows versus R&D losses at spun-off drug-discovery unit Yuhno-via, GLP-1 diabetes and obesity pipeline, licensing-out upside, Ildong Holdings structure, drug-pricing regulation risk, and balance-sheet improvement.

Ildong Pharmaceutical 249420 Korea Stocks